170 related articles for article (PubMed ID: 28941732)
1. The adaptor protein alpha-syntrophin is reduced in human non-alcoholic steatohepatitis but is unchanged in hepatocellular carcinoma.
Rein-Fischboeck L; Pohl R; Haberl EM; Weiss TS; Buechler C
Exp Mol Pathol; 2017 Oct; 103(2):204-209. PubMed ID: 28941732
[TBL] [Abstract][Full Text] [Related]
2. Alpha-syntrophin null mice are protected from non-alcoholic steatohepatitis in the methionine-choline-deficient diet model but not the atherogenic diet model.
Rein-Fischboeck L; Haberl EM; Pohl R; Schmid V; Feder S; Krautbauer S; Liebisch G; Buechler C
Biochim Biophys Acta Mol Cell Biol Lipids; 2018 May; 1863(5):526-537. PubMed ID: 29474931
[TBL] [Abstract][Full Text] [Related]
3. Alpha-syntrophin deficiency protects against non-alcoholic steatohepatitis associated increase of macrophages, CD8
Rein-Fischboeck L; Haberl EM; Bajraktari G; Feder S; Pohl R; Eggenhofer E; Buechler C
Exp Mol Pathol; 2020 Apr; 113():104363. PubMed ID: 31881201
[TBL] [Abstract][Full Text] [Related]
4. Lipid abnormalities in alpha/beta2-syntrophin null mice are independent from ABCA1.
Hebel T; Eisinger K; Neumeier M; Rein-Fischboeck L; Pohl R; Meier EM; Boettcher A; Froehner SC; Adams ME; Liebisch G; Krautbauer S; Buechler C
Biochim Biophys Acta; 2015 May; 1851(5):527-36. PubMed ID: 25625330
[TBL] [Abstract][Full Text] [Related]
5. Alpha-syntrophin dependent expression of tubulin alpha 8 protein in hepatocytes.
Rein-Fischboeck L; Bajraktari G; Pohl R; Feder S; Eisinger K; Mages W; Haberl EM; Buechler C
J Physiol Biochem; 2018 Nov; 74(4):511-521. PubMed ID: 30033487
[TBL] [Abstract][Full Text] [Related]
6. Non-invasive biomarkers in non-alcoholic steatohepatitis-induced hepatocellular carcinoma.
Voiculescu M; Nanau RM; Neuman MG
J Gastrointestin Liver Dis; 2014 Dec; 23(4):425-9. PubMed ID: 25532002
[TBL] [Abstract][Full Text] [Related]
7. The different expression of tumor suppressors, RASSF1A, RUNX3, and GSTP1, in patients with alcoholic steatohepatitis (ASH) vs non-alcoholic steatohepatitis (NASH).
Jia Y; Ji P; French B; Tillman B; French SW
Exp Mol Pathol; 2019 Jun; 108():156-163. PubMed ID: 30951700
[TBL] [Abstract][Full Text] [Related]
8. The adaptor protein alpha-syntrophin regulates adipocyte lipid droplet growth.
Eisinger K; Rein-Fischboeck L; Pohl R; Meier EM; Krautbauer S; Buechler C
Exp Cell Res; 2016 Jul; 345(1):100-7. PubMed ID: 27242274
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA expression analysis in high fat diet-induced NAFLD-NASH-HCC progression: study on C57BL/6J mice.
Tessitore A; Cicciarelli G; Del Vecchio F; Gaggiano A; Verzella D; Fischietti M; Mastroiaco V; Vetuschi A; Sferra R; Barnabei R; Capece D; Zazzeroni F; Alesse E
BMC Cancer; 2016 Jan; 16():3. PubMed ID: 26728044
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the specificity of four commercially available antibodies to alpha-syntrophin.
Eisinger K; Froehner SC; Adams ME; Krautbauer S; Buechler C
Anal Biochem; 2015 Sep; 484():99-101. PubMed ID: 26079703
[TBL] [Abstract][Full Text] [Related]
11. Hepatic scavenger receptor BI is associated with type 2 diabetes but unrelated to human and murine non-alcoholic fatty liver disease.
Rein-Fischboeck L; Krautbauer S; Eisinger K; Pohl R; Meier EM; Weiss TS; Buechler C
Biochem Biophys Res Commun; 2015 Nov; 467(2):377-82. PubMed ID: 26431876
[TBL] [Abstract][Full Text] [Related]
12. Chemokine (CC-motif) receptor-like 2 mRNA is expressed in hepatic stellate cells and is positively associated with characteristics of non-alcoholic steatohepatitis in mice and men.
Zimny S; Pohl R; Rein-Fischboeck L; Haberl EM; Krautbauer S; Weiss TS; Buechler C
Exp Mol Pathol; 2017 Aug; 103(1):1-8. PubMed ID: 28600126
[TBL] [Abstract][Full Text] [Related]
13. Hepatocellular carcinoma and non-alcoholic steatohepatitis: The state of play.
Charrez B; Qiao L; Hebbard L
World J Gastroenterol; 2016 Feb; 22(8):2494-502. PubMed ID: 26937137
[TBL] [Abstract][Full Text] [Related]
14. Impact of circulating miR-122 for histological features and hepatocellular carcinoma of nonalcoholic fatty liver disease in Japan.
Akuta N; Kawamura Y; Suzuki F; Saitoh S; Arase Y; Kunimoto H; Sorin Y; Fujiyama S; Sezaki H; Hosaka T; Kobayashi M; Suzuki Y; Kobayashi M; Ikeda K; Kumada H
Hepatol Int; 2016 Jul; 10(4):647-56. PubMed ID: 27074850
[TBL] [Abstract][Full Text] [Related]
15. Elevated free cholesterol in a p62 overexpression model of non-alcoholic steatohepatitis.
Simon Y; Kessler SM; Gemperlein K; Bohle RM; Müller R; Haybaeck J; Kiemer AK
World J Gastroenterol; 2014 Dec; 20(47):17839-50. PubMed ID: 25548482
[TBL] [Abstract][Full Text] [Related]
16. The Role of RECK in Hepatobiliary Neoplasia Reveals Its Therapeutic Potential in NASH.
Dashek RJ; Diaz C; Chandrasekar B; Rector RS
Front Endocrinol (Lausanne); 2021; 12():770740. PubMed ID: 34745017
[TBL] [Abstract][Full Text] [Related]
17. Molecular Pathogenesis of Nonalcoholic Steatohepatitis- (NASH-) Related Hepatocellular Carcinoma.
Kutlu O; Kaleli HN; Ozer E
Can J Gastroenterol Hepatol; 2018; 2018():8543763. PubMed ID: 30228976
[TBL] [Abstract][Full Text] [Related]
18. Dietary cholesterol promotes steatohepatitis related hepatocellular carcinoma through dysregulated metabolism and calcium signaling.
Liang JQ; Teoh N; Xu L; Pok S; Li X; Chu ESH; Chiu J; Dong L; Arfianti E; Haigh WG; Yeh MM; Ioannou GN; Sung JJY; Farrell G; Yu J
Nat Commun; 2018 Oct; 9(1):4490. PubMed ID: 30367044
[TBL] [Abstract][Full Text] [Related]
19. Cancer-related gene expression is associated with disease severity and modifiable lifestyle factors in non-alcoholic fatty liver disease.
Arendt BM; Teterina A; Pettinelli P; Comelli EM; Ma DWL; Fung SK; McGilvray ID; Fischer SE; Allard JP
Nutrition; 2019 Jun; 62():100-107. PubMed ID: 30870804
[TBL] [Abstract][Full Text] [Related]
20. Chemerin in a Mouse Model of Non-alcoholic Steatohepatitis and Hepatocarcinogenesis.
Haberl EM; Pohl R; Rein-Fischboeck L; Feder S; Sinal CJ; Buechler C
Anticancer Res; 2018 May; 38(5):2649-2657. PubMed ID: 29715085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
